[1] 生育补贴怎么补？“带娃难”如何缓解？各地持续探索完善[OL]. (2024-12-28)[2024-12-30]. https://www.chinanews.com.cn/sh/2024/12-28/10343978.shtml.
[2] Chambers GM, Paul RC, Harris K, et al. Assisted reproductive technology in Australia and New Zealand: cumulative live birth rates as measures of success[J]. Med J Aust, 2017, 207(3): 114-118. DOI: 10.5694/mja16.01435.
[3] 刘国恩. 中国药物经济学评价指南2020[M]. 北京: 中国市场出版社, 2020.
[4] Tonin FS, Aznar-Lou I, Pontinha VM, et al. Principles of pharmacoeconomic analysis: the case of pharmacist-led interventions[J]. Pharm Pract (Granada), 2021, 19(1): 2302. DOI: 10.18549/PharmPract.2021.1.2302.
[5] Barnhart KT. Live birth is the correct outcome for clinical trials evaluating therapy for the infertile couple[J]. Fertil Steril, 2014, 101(5): 1205-1208. DOI: 10.1016/j.fertnstert.2014.03.026.
[6] Tjon-Kon-Fat RI, Bensdorp AJ, Bossuyt PM, et al. Is IVF-served two different ways-more cost-effective than IUI with controlled ovarian hyperstimulation?[J]. Hum Reprod, 2015, 30(10): 2331-2339. DOI: 10.1093/humrep/dev193.
[7]Wang Y, Li R, Yang R, et al. Intracytoplasmic sperm injection versus conventional in-vitro fertilisation for couples with infertility with non-severe male factor: a multicentre, open-label, randomised controlled trial[J]. Lancet, 2024, 403(10430): 924-934. DOI: 10.1016/S0140-6736(23)02416-9.
[8] Lee M, Lofgren KT, Thomas A, et al. The cost-effectiveness of preimplantation genetic testing for aneuploidy in the United States: an analysis of cost and birth outcomes from 158,665 in vitro fertilization cycles[J]. Am J Obstet Gynecol, 2021, 225(1): 55.e1-55.e17. DOI: 10.1016/j.ajog.2021.01.021.
[9] Fiddelers AA, van Montfoort AP, Dirksen CD, et al. Single versus double embryo transfer: cost-effectiveness analysis alongside a randomized clinical trial[J]. Hum Reprod, 2006, 21(8): 2090-2097. DOI: 10.1093/humrep/del112.
[10] ESHRE Guideline Group on the Number of Embryos to Transfer, Alteri A, Arroyo G, et al. ESHRE guideline: number of embryos to transfer during IVF/ICSI†[J]. Hum Reprod, 2024, 39(4): 647-657. DOI: 10.1093/humrep/deae010.
[11] Maheshwari A, Bell JL, Bhide P, et al. Elective freezing of embryos versus fresh embryo transfer in IVF: a multicentre randomized controlled trial in the UK (E-Freeze)[J]. Hum Reprod, 2022, 37(3): 476-487. DOI: 10.1093/humrep/deab279.
[12]Bühler K, Roeder C, Schwarze JE, et al. Cost-effectiveness analysis of recombinant human follicle-stimulating hormone alfa(r-hFSH) and urinary highly purified menopausal gonadotropin (hMG) based on data from a large German registry[J]. Best Pract Res Clin Obstet Gynaecol, 2022, 85(Pt B): 188-202. DOI: 10.1016/j.bpobgyn.2022.02.002.
[13] Schwarze JE, Venetis C, Iniesta S, et al. Originator recombinant human follitropin alfa versus recombinant human follitropin alfa biosimilars in Spain: a cost-effectiveness analysis of assisted reproductive technology related to fresh embryo transfers[J]. Best Pract Res Clin Obstet Gynaecol, 2022, 85(Pt B): 203-216. DOI: 10.1016/j.bpobgyn.2022.01.011.
[14] Li H, He W, Lin H, et al. Recombinant human follicle-stimulating hormone in controlled ovarian hyperstimulation with assisted reproductive technology in China: a cost-effectiveness analysis[J]. Risk Manag Healthc Policy, 2024, 17: 1387-1394. DOI: 10.2147/RMHP.S456277.
[15] Schertz J, Worton H. Patient evaluation of the redesigned follitropin alfa pen injector[J]. Expert Opin Drug Deliv, 2017, 14(4): 473-481. DOI: 10.1080/17425247.2017.1289174.